Literature DB >> 14568811

Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.

Thomas D Marcotte1, Reena Deutsch, J Allen McCutchan, David J Moore, Scott Letendre, Ronald J Ellis, Mark R Wallace, Robert K Heaton, Igor Grant.   

Abstract

BACKGROUND: Neuropsychological (NP) impairment is a relatively common sequela in human immunodeficiency virus (HIV)-infected individuals with advanced disease. Early antecedents of NP dysfunction, however, remain poorly understood.
OBJECTIVE: To determine whether early markers of immunocompetence and viral replication in individuals who have undergone seroconversion would be of prognostic value in identifying subjects who would become cognitively impaired.
METHODS: Seventy-four subjects with estimable seroconversion dates and normal cognition at baseline (a median of 1 year after seroconversion) received NP and laboratory evaluations, including reverse transcription-polymerase chain reaction measurements of plasma (N = 74) and cerebrospinal fluid (n = 47) levels of HIV RNA. Subjects were followed up longitudinally, and were considered to have reached the end point if they became cognitively impaired.
RESULTS: Using Kaplan-Meier estimates, the subgroups with the most rapid progression to NP impairment were (1) subjects with early reductions in CD4 counts (<400 cells/microL at baseline; P =.007) and (2) those with elevated plasma HIV RNA values (>4.5 log10 copies/mL; P =.03) early after seroconversion. Using proportional hazards modeling, the highest-risk subjects had both CD4 counts less than 400 cells/microL and HIV RNA levels greater than 4.5 log10 copies/mL (risk ratio, 6.0; P =.01). In most subjects (7/9 [78%]), NP impairment developed before an acquired immunodeficiency syndrome-defining illness.
CONCLUSIONS: Neurocognitive outcomes in HIV are strongly influenced by very early systemic virological and immunological events. Patients with high plasma levels of HIV RNA and low CD4 counts early after infection should be aggressively treated to prevent immunological decline and NP deterioration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568811     DOI: 10.1001/archneur.60.10.1406

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  35 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

Review 2.  [HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management].

Authors:  C Eggers
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

Review 3.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

Authors:  Suzi Hong; William A Banks
Journal:  Brain Behav Immun       Date:  2014-10-22       Impact factor: 7.217

4.  Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection.

Authors:  Erica Weber; Erin E Morgan; Jennifer E Iudicello; Kaitlin Blackstone; Igor Grant; Ronald J Ellis; Scott L Letendre; Susan Little; Sheldon Morris; Davey M Smith; David J Moore; Steven Paul Woods
Journal:  J Neurovirol       Date:  2012-12-19       Impact factor: 2.643

5.  Neuropsychological test performance before and after HIV-1 seroconversion: the Multicenter AIDS Cohort Study.

Authors:  Quynh T Vo; Christopher Cox; Xiuhong Li; Lisa P Jacobson; Rosemary McKaig; Ned Sacktor; Ola A Selnes; Eileen Martin; James T Becker; Eric N Miller
Journal:  J Neurovirol       Date:  2012-12-11       Impact factor: 2.643

6.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

Review 7.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Does Older Age Confer an Increased Risk of Incident Neurocognitive Disorders Among Persons Living with HIV Disease?

Authors:  David P Sheppard; Steven Paul Woods; Mark W Bondi; Paul E Gilbert; Paul J Massman; Katie L Doyle
Journal:  Clin Neuropsychol       Date:  2015-08-26       Impact factor: 3.535

9.  Effort and neuropsychological performance in HIV-infected individuals on stable combination antiretroviral therapy.

Authors:  Robert Paul; Gina Rhee; Laurie M Baker; Florin Vaida; Sarah A Cooley; Beau M Ances
Journal:  J Neurovirol       Date:  2017-09-11       Impact factor: 2.643

Review 10.  Emerging issues in the neuropsychology of HIV infection.

Authors:  Jessica Foley; Mark Ettenhofer; Matthew Wright; Charles H Hinkin
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.